Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Don't run before you can walk.

Literature DB >> 23007837

Don't run before you can walk.

Licia Rivoltini, Andrea Marrari, Chiara Castelli, Sergio Villa, Riccardo Valdagni.

Abstract

Mesh：

Substances：

Year: 2012 PMID： 23007837 DOI： 10.1038/nrurol.2012.103-c1

Source DB: PubMed Journal: Nat Rev Urol ISSN： 1759-4812 Impact factor: 14.432

Keyword Cloud
References

× No keyword cloud information.

11 in total

1. Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity.

Authors: Padmanee Sharma; Christopher Logothetis
Journal: Nat Rev Urol Date: 2012-05-08 Impact factor: 14.432

2. Immunotherapy for prostate cancer: walk, don't run.

Authors: Charles G Drake
Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544

Review 3. Vaccination therapy in prostate cancer.

Authors: Andrea Marrari; Manuela Iero; Lorenzo Pilla; Sergio Villa; Roberto Salvioni; Riccardo Valdagni; Giorgio Parmiani; Licia Rivoltini
Journal: Cancer Immunol Immunother Date: 2006-10-10 Impact factor: 6.968

4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

5. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors: Alfons J M van den Eertwegh; Jurjen Versluis; H Pieter van den Berg; Saskia J A M Santegoets; R Jeroen A van Moorselaar; Tim M van der Sluis; Helen E Gall; Thomas C Harding; Karin Jooss; Israel Lowy; Herbert M Pinedo; Rik J Scheper; Anita G M Stam; B Mary E von Blomberg; Tanja D de Gruijl; Kristen Hege; Natalie Sacks; Winald R Gerritsen
Journal: Lancet Oncol Date: 2012-02-10 Impact factor: 41.316

6. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors: Ravi A Madan; Mahsa Mohebtash; Philip M Arlen; Matteo Vergati; Myrna Rauckhorst; Seth M Steinberg; Kwong Y Tsang; Diane J Poole; Howard L Parnes; John J Wright; William L Dahut; Jeffrey Schlom; James L Gulley
Journal: Lancet Oncol Date: 2012-02-10 Impact factor: 41.316

Don't run before you can walk.

1. Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity.

2. Immunotherapy for prostate cancer: walk, don't run.

Review 3. Vaccination therapy in prostate cancer.

4. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

5. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

6. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Review 7. Cancer/testis (CT) antigens: potential targets for immunotherapy.

8. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.

Review 9. The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.

Review 10. Antiphospholipid syndrome infectious origin.